Who does the MHRA actually contact when a complaint needs tracing back to a batch, or when a technical file is requested at short notice? For any manufacturer established outside the UK, the answer is the UK Responsible Person — the UK-based representative appointed under the UK Medical Devices Regulations 2002, as amended, to act as the manufacturer’s official point of contact with the regulator.
Any manufacturer established outside the UK that wants to place medical devices or IVDs on the market in England, Scotland or Wales — defined together as Great Britain — must appoint a UKRP. The UKRP acts as the official representative of that manufacturer before the MHRA, the Medicines and Healthcare products Regulatory Agency that regulates the UK medical devices market. Northern Ireland follows a different regime under the Northern Ireland Regulations 2021, so a single UKRP appointment does not automatically cover both markets — the manufacturer’s own compliance system still has to respond once contact is made, because appointing a UKRP does not, on its own, resolve how information or responsibility will move.
Treated as a one-off registration formality, the appointment can look complete the moment the paperwork is filed. Treated instead as a governance decision — covering how information moves between the manufacturer’s quality system and the UK-based party representing it to the MHRA — it tends to hold up better once real requests start arriving. The weak points, when they appear, usually show up as a document request that takes longer than it should to answer, or a question nobody was clearly assigned to own.
What a UK Responsible Person is — and What it is Not
Non-UK manufacturers wishing to place medical devices or in vitro diagnostic devices on the Great Britain market — England, Scotland and Wales — must appoint a UK Responsible Person (UKRP), as required by the UK Medical Devices Regulations 2002, as amended. The UKRP acts as the official representative of the foreign manufacturer before the MHRA, which regulates the UK medical devices market.
In practice, manufacturers still need to define how information and responsibilities will flow between the manufacturer and the UKRP, since the appointment itself does not settle day-to-day coordination — who holds which document, who answers which request, and how quickly. Depending on the agreement, a UKRP’s scope for medical devices and IVDs can extend to MHRA registration support, documentation monitoring, labeling compliance checks, registration activities in the DORS database and ongoing regulatory communication. ALTRION, through its London-based entity, provides this kind of full UK responsible person representation — one way the role can be scoped in practice, rather than a universal definition of what every UKRP arrangement must include.
What a UKRP is not is a substitute for the manufacturer’s quality management system. Conformity assessment, risk management and the technical documentation behind a device’s claims remain the manufacturer’s responsibility; the UKRP’s role is representation and coordination, not a parallel compliance function. A manufacturer selling into both the EU and Great Britain should treat a UKRP arrangement and an EU Authorised Representative arrangement as separate pieces of infrastructure, not interchangeable ones, even where the device itself is identical.
Why Compliance Responsibilities Are Growing for International Manufacturers in the UK
MHRA guidance on regulating medical devices in the UK has not stayed fixed since the post-Brexit framework came into force. The guidance page was first published at the end of 2020 and has been revised repeatedly since, most recently in February 2026. Fees have shifted too: the standard fee per application changed to £240 from 8 February 2024. Neither fact says much about enforcement intensity on its own, but together they suggest that registration requirements, fees and guidance text are reviewed on an ongoing basis — and a UKRP arrangement that was adequate at the point of appointment can fall behind if nobody revisits it.
There is also a practical reason the coordination burden tends to grow rather than stay flat. Each new device variant, each labelling revision, each change of importer or distributor adds a data point the UKRP needs visibility into. A manufacturer with a handful of device families and one GB distributor carries a modest load. The same manufacturer years later, with a larger portfolio and an accumulated history of minor changes, is managing a noticeably more complex information flow — even where the underlying regulatory text has not itself changed.
Transitional arrangements around CE and UKCA marking add a further layer that needs tracking rather than assuming. The validity of CE certificates issued from 25 May 2017 and still valid on 26 May 2022 has been extended to 31 December 2027 for Annex II List A, Annex II List B, and self-test IVD devices. A manufacturer relying on that extension needs a UKRP who can say, product by product, which transitional rule applies — because the rules are not uniform across device categories.
The UK Responsible Person as a Compliance Interface: Three Flows to Design
Treating the UKRP relationship as an operating model, rather than a one-off appointment, means thinking about three information flows deliberately instead of letting them happen by accident.
Information flow. Registration is the clearest example. A Certificate of Free Sale can only be ordered for medical devices and IVDs already registered through the MHRA’s Device Online Registration System, DORS, and IVDs intended for performance evaluation cannot be included on CFS orders at all. A CFS, in turn, can only be ordered by a UK-based manufacturer, a UK Responsible Person, or a Northern Ireland-based authorised representative — and the MHRA does not itself verify export-market compliance when issuing one; that responsibility sits with the applicant. A practical safeguard is giving the UKRP standing access to current technical documentation and labelling versions before it manages DORS listings, since registration data that falls out of step with the product actually being sold is difficult to notice until someone — a customer, an auditor — asks a pointed question.
Safety flow. Post-market surveillance signals, complaints and vigilance decisions raise a similar question: who assesses reportability for the UK market specifically, who drafts the submission, and who tracks it through to resolution. Depending on the agreement, vigilance coordination may be included in the UKRP scope — if it is, that division of labour is worth writing explicitly rather than assuming it is covered by default. A practical approach is to review procedures originally built around a different regulator and add a UK-specific step, since reportability assessments for the GB market are not necessarily identical to those used elsewhere.
Supply-chain flow. A practical approach is to treat importers and distributors as a primary source of the operational data both the UKRP and the manufacturer need — stock records, delivery dates, sometimes the first complaint a clinician raises. Where traceability depends on unique device identification or batch and serial records, building that handover into the distribution contract, rather than assuming it will happen informally, keeps the supply-chain flow reliable when it is tested by a real incident. A fair question for any manufacturer to ask is whether registration, documentation checks and vigilance coordination can realistically sit with one point of contact, or whether splitting them across several providers adds more coordination cost than it saves — the answer depends on portfolio complexity more than on any fixed rule.
Where Manufacturers Most Often Fail — and How to Prevent it
Several patterns can surface once a UKRP relationship has been running for a year or two, after the initial registration work is done and routine operation begins. None of them are regulatory failures in themselves, but each one can precede one.
- Treating the UKRP as a mailbox. No escalation path is defined for urgent requests, and the UKRP has no standing access to evidence — so a request can turn into a scramble to locate documents inside the manufacturer’s own systems.
- Fragmented document control. UK-specific labeling and IFU versions can drift out of sync with EU or other regional versions when change control is not set up to flag a UK-specific review step.
- Unclear vigilance governance. If nobody has explicitly agreed who assesses reportability for the UK market, decisions can default to whoever answers first — not necessarily the right person.
- Weak economic-operator contracts. If importers and distributors are not contractually bound to supply complaint or traceability data within a defined timeframe, the UKRP’s information flow depends on goodwill rather than obligation.
Addressing these patterns is less about new technology and more about explicit ownership: naming who is responsible for each UK-specific task, writing procedures that reference UK requirements directly rather than language borrowed from another market’s process, giving the UKRP standing access to documents rather than depending on email, and testing the arrangement periodically rather than waiting for a real incident to reveal the gaps.
Operational Responsibilities That Typically Expand After UK Market Entry
Initial registration is the visible milestone, but what follows is less visible and more continuous. Registration maintenance does not stand still: new devices, variants and discontinuations need to be reflected in DORS listings, since that registration is also the gateway a Certificate of Free Sale depends on later — a connection worth keeping in mind whenever an export order is being planned alongside a portfolio change.
Change control also acquires a UK dimension that is easy to miss. A labelling update, a change in intended purpose, or a supplier change affecting compliance each warrant a UK-specific assessment, rather than an assumption that a wider review at group level automatically covers it. Post-market routines — complaint trending, periodic reviews, CAPA linkage, and the ability to support a field safety corrective action if one becomes necessary — test, in practice, whether documents and decisions can be produced consistently whenever the MHRA or another authority asks for them.
Building a Workable Governance Model Between Manufacturer and UKRP
A durable UKRP arrangement starts with governance, not paperwork. The MHRA treats the UK Responsible Person as the official UK point of contact for the overseas manufacturer; the manufacturer’s own compliance system still needs to respond without unnecessary delay once the UKRP is asked for something — the appointment is the start of the work, not the end of it.
Consider a routine scenario: an export customer requests a Certificate of Free Sale for a device already sold elsewhere. The MHRA will only issue one for devices already registered in DORS, and only a UK-based manufacturer, a UK Responsible Person, or an NI-based authorised representative is entitled to place that order. If the UKRP cannot confirm DORS status without unnecessary delay, the export order stalls — a concrete, if unglamorous, cost of a weak information flow. A practical approach is to define, in writing, how quickly such a confirmation should be available, rather than leaving it to whoever happens to answer the email that week.
Beyond that scenario, a regular communication cadence — a periodic post-market surveillance sync, a compliance review, something feeding the manufacturer’s management review — helps keep the relationship active rather than dormant between registration events. None of this is mandated by the regulation itself; it is simply a structure that, in our experience, separates an arrangement that functions smoothly from one that only gets tested when something goes wrong.
What to Include in a UKRP Agreement to Match Real-world Compliance Pressure
A UKRP agreement is easier to rely on later if a few things are explicit from the start:
- Scope: which device families, legacy products, accessories and software updates are covered, and whether IVDs and medical devices sit under separate schedules.
- Who holds documentation, and how it stays available for an inspection or request.
- Who coordinates vigilance reporting, and within what internal timeline.
- Who supports a field safety corrective action if one becomes necessary.
- How confidentiality and data protection are maintained while still allowing the access the UKRP needs.
- How records transfer and market continuity are protected if the UKRP relationship ends.
KPIs give the arrangement something to review periodically: response times against agreed expectations, completeness of the documentation set the UKRP can access, and a track record of supporting past registration or vigilance work — treated as inputs to a periodic review rather than fixed targets set once and forgotten.
Common Questions About the UK Responsible Person Role
Do I need a UKRP if I am established outside the UK?
Yes, if the device is placed on the Great Britain market. Non-UK manufacturers wishing to place medical devices or IVDs on the market in England, Scotland or Wales must appoint a UK Responsible Person under the UK Medical Devices Regulations 2002, as amended.
Does Northern Ireland follow the same rules as Great Britain?
No. Great Britain is defined as England, Wales and Scotland, and under the Northern Ireland Regulations 2021, different rules apply in Northern Ireland compared with Great Britain.
What is DORS, and why does it matter?
DORS is the MHRA’s Device Online Registration System, used to register medical devices and IVDs for the UK market. A Certificate of Free Sale can only be ordered for devices already registered through DORS.
Who can actually order a Certificate of Free Sale?
A CFS can only be ordered by a UK-based manufacturer, a UK Responsible Person, or a Northern Ireland-based authorised representative. The MHRA itself does not verify export-market compliance when issuing the certificate.
How much does MHRA registration cost per application?
The standard MHRA fee per application changed to £240 from 8 February 2024, according to current guidance.
